Overview of Dr. Kirtane
Dr. Kedar Kirtane is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Florida College of Medicine and has been in practice 7 years. He is one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 30 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2015 - 2018
- Duke University HospitalResidency, Internal Medicine, 2012 - 2015
- University of Florida College of MedicineClass of 2012
Certifications & Licensure
- FL State Medical License 2018 - 2026
- WA State Medical License 2015 - 2019
- NC State Medical License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer.Benjamin Lee, Sarah S Chehab, Wenyi Fan, Michael J Schell, Kedar S Kirtane
Journal of Oncology Pharmacy Practice. 2024-12-01 - 2 citationsT-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman
Cancer Discovery. 2024-11-01 - Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.Nabil F Saba, Ritu Chaudhary, Kedar Kirtane, Angelo Marra, Asari Ekpenyong
Clinical Cancer Research. 2024-10-15
Press Mentions
- I AM INCLUDED: 8 Best Practices for Sites to Drive More Inclusive Clinical TrialsDecember 13th, 2024
- Getting Help for Sexual Health Problems When You Have Head and Neck Cancer: An Expert Q&AApril 14th, 2022
- Moffitt Doctors Say They're Closing in on Cures for Certain Common CancersFebruary 8th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: